32 slides from Advanced Enzyme Technologies's earnings presentation, Aug 10, 2024
Slide 1: Exchange filing cover letter: Earnings Presentation
^ tivancerl enzymes Where ENZYME is Lite Advanced Enzyme Technologies Ltd . CIN: L2420OMH1989PLC051018 Sun Magnetics, A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane ( W)-400 604, India Tel: + 91-22-4170 3200, Fax: + 91-22-2583 5159 Email: info@advancedenzymes.com, www.advancedenzymes.com Aug
Slide 2: Advanced Enzyme Technologies Limited Earnings Presentation August 2024
advanced enzymes Where ENZYME is Life Advanced Enzyme Technologies Limited Earnings Presentation | August 2024
Slide 3: Safe Harbour Statement
Safe Harbour Statement ^ Manced enzymes Where ENZYME is Lite This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical fac
Slide 4: Agenda
/ ^ \ / ^^ dincpcJ enzymes Where ENZYME is Life 1 2 3 Result Summary Business Geographical Q1 FY25 Performance Performance Page: 04 Page: 06 Page: 10 4 5 6 7 Result Summary Unique Focus Area Shareholders’ FY24 Investment Case Going Ahead Information Page: 12 Page: 24 Page: 28 Page: 30 Earnings Prese
Slide 5: Results Summary – Q1 FY25 (Consolidated) Y-o-Y
Results Summary – Q1 FY25 (Consolidated) Y-o-Y ^ Manced enzymes Where ENZYME is Lite Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,545 512 I 1,473 350 440 294 05% 16% 19% Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Q1 FY24 Q1 FY25 Revenue grew by 5% on y-o-y basis to EBITDA grew by 16% to ₹ 512 million in the PAT
Slide 6: Results Summary – Q1 FY25 (Consolidated) Q-o-Q
Results Summary – Q1 FY25 (Consolidated) Q-o-Q ^ Manced enzymes Where ENZYME is Lite Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) I 1,578 1,545 554 350 I 512 299 02% 08% 17% Q4 FY24 Q1 FY25 Q4 FY24 Q1 FY25 Q4 FY24 Q1 FY25 Revenue de-grew by 2% on q-o-q basis to ₹ 1,545 million in the EBITDA de-grew by 8
Slide 7: Human Nutrition
Human Nutrition 1,107 (₹ in Million) ^ Mancecl enzymes Where ENZYME is Lite 994 1,059 1,024 1,012 Commentary: 939 934 877 807 • The human nutrition segment contributed around 65% during the quarter in the total revenue from operations. • This segment grew by 2% during the quarter from ₹ 994 million
Slide 8: Animal Nutrition
Animal Nutrition (₹ in Million) ^ Mancecl enzymes Where ENZYME is Lite 206 Commentary: 185 172 175 173 172 156 158 162 • The Animal nutrition segment contributed about 11% during the quarter in the total revenue from operations • This segment grew by 9% on y-o-y basis to ₹ 172 million in Q1 FY25 as
Slide 9: Industrial Bio-processing
Industrial Bio-processing \nced enzymes Where ENZYME is Lite (₹ in Million) 243 258 251 Commentary: 236 226 224 193 192 • The Industrial Bio-Processing segment 183 contributed around 16% during the quarter in the total revenue from operations • This segment outperformed by 12% on y-o-y basis to ₹ 25
Slide 10: Specialized Manufacturing
Specialized Manufacturing 113 111 (₹ in Million) 110 ^ Mancecl enzymes Where ENZYME is Lite 97 103 104 Commentary: 83 86 • This segment contributed about 7% during the 65 quarter to the total revenue from operations • This segment outperformed by 13% on y-o-y basis at ₹ 110 million in Q1 FY25, and o
Slide 11: Geographical performance
Geographical performance ^ Mancecl enzymes Where ENZYME is Lite (₹ in Million) 48% 38% 5% 7% 2% r W f j0t Sr • ’we Rest of the India Americas Europe Asia* World +0% +27% +13% -7% -65% Q1 FY25 740 Q1 FY25 591 Q1 FY25 74 Q1 FY25 111 Q1 FY25 29 Q1 FY24 737 Q1 FY24 467 Q1 FY24 66 Q1 FY24 119 Q1 FY24 84
Slide 12: Profit & Loss (Consolidated) – Q1 FY25
Profit & Loss (Consolidated) – Q1 FY25 ^ Manced enzymes Where ENZYME is Lite (₹ in Million) Q1 FY25 Q4 FY24 Q1 FY24 Y-o-Y Q-o-Q FY24 FY23 Particulars Y-o-Y (%) Un-Audited Audited Un-Audited (%) (%) Audited Audited Income from Operations 1,545 1,578 1,473 5% -2% 6,239 5,406 15% Expenses 1,120 1,118 1
Slide 13: Result summary - FY24 (Consolidated) Y-o-Y
Result summary - FY24 (Consolidated) Y-o-Y ^ Mancecl enzymes Where ENZYME is Life (₹ in Million) Revenue* (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 0A 6,239 2,045 1,370 5,406 1,564 1,039 1 1 1 FY23 FY24 FY23 FY24 FY23 FY24 Human Nutrition Animal Nutrition Bio Processing Specialized Manufacturing +18% -5% +21%
Slide 14: Revenue Mix – FY24 vs. FY23
Revenue Mix – FY24 vs. FY23 FY24 ^ Mancecl enzymes Where ENZYME is Lite 3% 7% 7% 15% 6% 50% 11% 67% 34% Human Nutrition Animal Nutrition Bio-Processing Specialised Manufacturing India Americas Europe Asia (ex-India) Rest of the World FY23 2% 6% 9% 15% 7% 47% 13% 35% 66% Human Nutrition Animal Nutrit
Slide 15: Strong Financial Performance – FY24
Strong Financial Performance – FY24 Revenue from Operations EBIDTA & EBIDTA Margin (%) ^ Manced enzymes Where ENZYME is Lite (₹ in Million) 6,239 2,500 46% 46% 50% 5,294 5,406 38% 45% 5,018 4,440 2,000 40% 29% 33% 35% 1,500 30% 25% 1,000 20% 15% 500 10% 2,023 2,316 2,014 1,564 2,045 5% 0 0% FY 20 FY
Slide 16: Strong Financial Performance – FY24
Strong Financial Performance – FY24 Net Working Capital (Days) Net Worth (₹ mn) ^ Manced enzymes Where ENZYME is Lite 13,241 135 135 12,351 132 10,886 9,709 8,397 120 115 FY 20 FY 21 FY 22 FY 23 FY 24 FY 20 FY 21 FY 22 FY 23 FY 24 ROE (%) & ROCE (%) Net Debt to Equity (x) 22.44% 21.94% 0.02 0.02 0.0
Slide 17: Balance Sheet (Consolidated)
Balance Sheet (Consolidated) ^ Manced enzymes Where ENZYME is Lite (₹ in Million) FY24 FY23 FY22 Particulars Audited Audited Audited Assets Property, plant and equipment 2,765 2,732 2,622 Capital work-in-progress 411 215 151 Intangible assets 479 550 609 Goodwill 3,253 3,209 2,961 Other non-current
Slide 18: Annexure
Annexure
Slide 19: Company Overview, Mission and Vision
Company Overview Advanced enzvmt Where ENZYME is Life What are Probiotics? Advanced Enzymes is a research driven company with global Probiotics are live microorganisms, when administered in sufficient amount, leadership in the manufacturing of enzymes and probiotics. confer health benefits to human
Slide 20: A Rising Global Star
Advanced Enzyme Technologies Limited – A Rising Global Star Priced enzymes Where ENZYME is Lite 9 68+ 400+ 700+ Manufacturing Units India – 8 | USA - 1 7 Enzymes & Probiotics Proprietary Products © Customers Worldwide O ITS R&D Units India – 5 | USA – 1 | 45+ @ 750+ 13* 1st Indian Enzyme gpi Wms~£ G
Slide 21: Brief History and Evolution
Brief History and Evolution ^ ifrancecl enzymes Where ENZYME is Lite • Equity investment • 4 food enzymes got by Kotak Private approved as a Equity processing aid with • Takeover of Food Safety Standard • Received NIH grant for • Received approval for 2 Advanced Authority of India ImmunoSEB and food
Slide 22: Board of Directors
Board of Directors Advanced enzymes Where ENZYME is Life Mr. Vasant Rathi Mr. Mukund M. Kabra Mr. Pramod Kasat Promoter Chairman and Non-Executive Director Whole-time Director Independent Director Ms. Rasika Rathi Mr. Vinod Jajoo Mr. Sunny Sharma Non-Executive Director Independent Director Non-Execu
Slide 23: Management Team
Management Team ^ Mancecl enzymes Where ENZYME is Life ' El m Mr. Beni Prasad Rauka Mr. Dipak Roda Mr. Harshad Doshi Ms. Martina Doering Group Chief Financial Officer Vice President / Market & Business CFO & COO - Advanced Enzymes, USA Managing Director /Head Of Business Development Development - ev
Slide 24: How Big is the Opportunity?
How Big is the Opportunity? Global Enzymes Market ^ Manced enzymes Where ENZYME is Lite Global Probiotics Market Grow at a $6Bn 8% Grow at a CAGR 7.75% CAGR 6% $11.3Bn CY 2023-28 till 2030 $7Bn $923Mn 11% $57Bn $400Mn 81% $70Bn $1.85Bn $3.57Bn $250Mn $500Mn $800Mn Animal Feed Dietary Supplements Fun
Slide 25: What Makes AETL a Unique Investment Case?
What Makes AETL a Unique Investment Case? ^ Mancecl enzymes Where ENZYME is Lite Specialized Business with High Entry Barriers a Strong Research & Development Capabilities ¥ Integrated Player with Presence Across the Enzyme Value Chain <sjb Inherent Diversification in the Business Model Significant
Slide 26: Integrated Player with Presence Across the Enzyme Value Chain
^ saiuAzua paoupw Integrated Player with Presence Across the Enzyme Value Chain ajnsi 3mzN33jaim Research & Development Manufacturing Marketing & Distribution Earnings Presentation | August 2024 25
Slide 27: What we are Aiming in the Opportunity?
What we are Aiming in the Opportunity? \nced enzymes Where ENZYME is Lite Addressable market for AETL over next 5 AETL’s Current Share of Revenue Focus Area Opportunity Size years** FY24 FY23 Human Nutrition $ 400 mn $ 200 mn $ 43.5 mn, 58% $ 38.8 mn, 58% Bio-Catalysis $ 60 mn $ 30 mn* $ 3.3 mn, 4%
Slide 28: Specialized Business With High Entry Barriers
Specialized Business With High Entry Barriers Technocrat Global Promoters Competitiveness Amongst the Lowest Cost Cumulative experience of 7+ decades Manufacturers in the World in the global enzyme industry (Benchmarked both in terms of Capex & Opex) Sustained Research Diverse Product Range & Develo
Slide 29: Future Growth Drivers
Future Growth Drivers ^ Mancecl enzymes Where ENZYME is Lite Continued Broaden & Deepen Inorganic Investment in R&D Geographical Presence Expansion o Acquisition of Key Technologies, Competencies & o Identify Product gaps and Develop new Enzymes, o Increased focus on high return applications where S
Slide 30: Focus Areas Going Ahead
Focus Areas Going Ahead ^ Manced enzymes Where ENZYME is Lite • Continuing conduct trials and studies to bring newer and effective nutritional products, which may improve the efficacy of animal feeds • Registering and introducing more products in the domestic as well as in the international markets.
Slide 31: Shareholders Information
Shareholders Information ^ Mancecl enzymes Where ENZYME is Lite Stock Data (As on 9th Aug 2024) Top Institutional Holders (As on 2nd Aug 2024) Institutions OS (%) Market Capitalization (₹) 46,407 mn ORBIMED ASIA III MAURITIUS 12.08 Shares Outstanding 111.82 mn NALANDA INDIA EQUITY FUND 8.46 HDFC MF
Slide 32: Thank you
Private Limited Y Sun Infotech 9 'Min Park Soparkar Industries HotelMh09 Shetkari Shehnai Hal! 9 IIFL Home Loan 09 &ratf Hotel Dwaraka Residency Centrum Business Square 9 Dnyt Hotels In Thane ^ Sun Crest Advanced Enzyme nsnrt Mahendra Dished Ends Pvt Shree Mahavir Jain Hospital 9 Technologies Ltd *